|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09997 KANGJI MEDICAL
Nominal 
8.890 +0.020 (+0.225%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 496,555 | 8.320% | 1,008,610 | 926,023 | 786,367 | 690,263 |
| Cost of Sales | (104,194) | 9.344% | (210,961) | (184,824) | (151,120) | (127,337) |
| Gross Profit | 392,361 | 8.052% | 797,649 | 741,199 | 635,247 | 562,926 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (1,337) | -- | 279 | (1,064) | 1,054 | (614) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (19,542) | 233.027% | (21,861) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 324,876 | -0.872% | 684,833 | 588,771 | 563,144 | 534,497 | |
| Taxation | (59,116) | 13.582% | (113,556) | (136,476) | (101,970) | (77,708) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 10,161 | 51,726 | 17,561 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 265,760 | -7.027% | 581,438 | 504,021 | 478,735 | 456,789 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (21,185) | -65.839% | (84,731) | (89,575) | (68,128) | (33,092) |
| Depreciation & Amortisation | 16,010 | 12.913% | 27,279 | 32,954 | 21,631 | 11,860 |
| Directors' Emoluments | -- | -- | 5,369 | 9,302 | 7,734 | 7,756 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 22.560 | -7.503% | 49.450 | 43.080 | 39.630 | 37.310 |
| DPS (cts) | 0.000 | -- | 24.000 | 140.000 | 18.450 | 14.610 |
| Dividend Payout Ratio (%) | -- | -- | 48.534% | 324.977% | 46.556% | 39.158% |
| Cash flow per share ($) | -- | -- | 0.476 | 0.361 | 0.264 | 0.356 |
| NBV per share ($) | 2.148 | -- | 2.175 | 2.999 | 2.766 | 2.617 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 265,760 |
| %Change | -7.027% |
| EPS / (LPS) | RMB 0.226 |
| NBV Per Share (¥) | RMB 2.148 |